CME Information

  • Release date: October 2020
  • Expiration date: September 2021
  • Estimated time to complete this activity: 3 hours
  • Type of hardware and software needed to participate in the activity: Windows/Mac computer with modern Internet Browsers like Chrome, IE, Safari or Firefox
  • If you have any questions regarding the website, please contact Veritas Institute for Medical Education, Inc. at 201-727-1115 x2340. If you have any questions regarding accreditation, please contact MER at: 800-421-3756.

This activity is jointly provided by Medical Education Resources, Inc., Veritas Institute for Medical Education, Inc., and the American Professional Society of ADHD and Related Disorders. This activity is supported by educational grants from Ironshore Pharmaceuticals, Supernus Pharmaceuticals Inc., and QB tech.

Target Audience
This activity has been designed to meet the educational needs of child and adolescent psychiatrists, primary care physicians, nurse practitioners, registered nurses, and other allied healthcare professionals, involved in the care of patients with attention-deficit/hyperactivity disorder (ADHD).

Program Overview
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children and adults. It is characterized by a persistent pattern of impulsiveness, inattention, and hyperactivity. The worldwide incidence is approximately 7.2% of children and adolescents.1 However, according to a recent national survey in the US, 9.4% of children ages 2 to 17 years had had an ADHD diagnosis, including 2.4% of children 2 to 5 years of age. There were 8.4% of children 2 to 17 years, equal to 5.4 million children, who currently had ADHD.2 Community-based estimates are even higher, 8.7 to 15.5%.3,4 Boys are more likely to be diagnosed with ADHD than girls, 13.2% vs. 5.6% respectively.5 ADHD is often diagnosed in childhood and lasts into adulthood in approximately 65-75% of cases.6 A systematic literature review suggests that the annual incremental costs for the disorder in the US are between $143 and $266 billion.7

Because ADHD affects so many people and the costs associated with the disease continue to rise, new and improved ways of managing these patients is crucial. This program will discuss the current understanding of the science behind the medications that are available/soon to be available, describe the current non-drug therapies which are available, discuss emerging technologies which may be of benefit for patients with ADHD, and examine ADHD-associated topics that create difficulties in clinician management of the disorder.

References:

  1. Thomas R, Sanders S, Doust J, et al. Prevalence of attention deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;135(4).
  2. Danielson ML, Bitsko RH, Ghandour RM, et al. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199–212.
  3. Wolraich ML, McKeown RE, Visser SN, et al. The prevalence of ADHD: its diagnosis and treatment in four school districts across two states. J Atten Disord. 2014;18(7):563–575.
  4. Rowland AS, Skipper BJ, Umbach DM, et al. The prevalence of ADHD in a population-based sample. J Atten Disord. 2015;19(9):741–754.
  5. Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011. J Am Acad Child Adolesc Psychiatry. 2014;53(1):34-46.
  6. Wilens TE, Faraone SV, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA. 2004;292(5):619-623.
  7. Doshi JA, Hodgkins P, Kahle J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51(10):990-1002.

Learning Outcome
To gain understanding and information regarding technologies, current and emerging treatment options, and clinical challenges associated with the diagnosis and management of ADHD in children and adolescents. 

Educational Objectives
After completing this activity, the participant should be better able to:
  • Analyze some of the problematic and unmet needs in managing ADHD in special populations or with comorbid conditions
  • Review those aspects of ADHD management centered around the currently available generic and branded medications used for treatment as well as emerging options engaged in clinical trials
  • Identify and understand the use of current and emerging technologies designed to assist in diagnosis, treatment and management of impairments associated with ADHD

Activity Chair/Content Planner

Stephen V. Faraone, PhD
Distinguished Professor
Departments of Psychiatry and Neuroscience & Physiology
Director of Research
Department of Psychiatry
SUNY Upstate Medical University
Syracuse, NY

Faculty

Joseph Biederman, MD
Chief, Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD
Director, The Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorders
Massachusetts General Hospital
Boston, MA

Ann Childress, MD
President at the Center for Psychiatry and Behavioral Medicine
Adjunct assistant professor in the Department of Psychiatry and Family Medicine
University of Nevada School of Medicine and Touro University
Las Vegas, NV

Samuele Cortese, MD, PhD Professor of Child and Adolescent Psychiatry within Psychology
University of Southampton
Southampton, UK

Andrew Cutler, MD
Clinical Associate Professor of Psychiatry
SUNY Upstate Medical University
Syracuse, New York
CEO, Florida Clinical Research Center, LLC
Bradenton, FL

Tanya E. Froehlich, MD
Director of Research, Division of Developmental and Behavioral Pediatrics
Associate Director, Developmental and Behavioral Pediatrics Fellowship
Associate Professor, UC Department of Pediatrics
University of Cincinnati Medical Center
Cincinnati, OH

Scott Kollins, PhD
Professor, Department of Psychiatry and Behavioral Sciences
Director, Duke ADHD Program
Duke University School of Medicine
Durham, NC

Gregory W. Mattingly, MD
Associate Clinical Professor
Washington University School of Medicine
St. Louis, MO
President, Midwest Research Group
Midwest Research Group
St. Charles, MO

Jesse McClelland, MD, MPh
Medical Director of Psychiatry Northwest™
Seattle, WA

James J. McGough, MD
Professor of Clinical Psychiatry at the Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine
Los Angeles, CA

Jeffrey Newcorn, MD
Professor of Psychiatry and Pediatrics Director, Division of ADHD and Learning Disorders
Icahn School of Medicine at Mount Sinai
Director, Pediatric Psychopharmacology
Mount Sinai Health System
New York, NY

Steven Pliszka, MD
Dielmann Distinguish Professor and Chair of the Department of Psychiatry
University of Texas Health Science Center
San Antonio, TX

Anthony L. Rostain, MD, MA
Professor of Psychiatry and Pediatrics
Co-Director, Adult ADHD Treatment and Research Program
Medical Director, Adult Neurodevelopmental Disorders Section
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Timothy E. Wilens, MD
Chief, Division of Child and Adolescent Psychiatry
Co-Director, Center for Addiction Medicine
Director, Substance Abuse Services in Pediatric Psychopharmacology
Massachusetts General Hospital
Boston, MA

Program Agenda

60 minutes

ADHD Conundrums

Joseph Biederman, MD

Tanya Froehlich, MD

Jeffrey Newcorn, MD

Steven Pliszka, MD

60 minutes

ADHD Medication: “What, Why, When, How”

Ann Childress, MD

Samuele Cortese, MD, PhD

Andrew Cutler, MD

Gregg Mattingly, MD

Timothy Wilens, MD

60 minutes

Technologies in ADHD

Scott Kollins, PhD

Jesse McClellend, MD

James McGough, MD

Anthony Rostain, MD


ACCREDITATION/DESIGNATION OF CREDIT
Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Veritas Institute for Medical Education, Inc., and American Professional Society of ADHD and Related Disorders (APSARD). Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates each enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Each CE activity provides 1.0 contact hours of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hours.

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.



The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name

Reported Financial Relationship

Type of Disclosure

Company

Joseph Biederman, MD

Grants/Research Support

Genentech, Headspace Inc., NIDA, Pfizer Pharmaceuticals, Roche TCRC Inc., Sunovion Pharmaceuticals Inc., Takeda/Shire Pharmaceuticals Inc., Tris

Consulting Fees (eg, Ad Boards)

Akili, Avekshan, Jazz Pharma, Shire/Takeda, Supernus

Royalty/Patent Holders

Biomarin, Bracket Global, Cogstate, Ingenix, Medavent Prophase, Shire, Sunovion, and Theravance

Ann C. Childress, MD

Grants/Research Support

Allergan, Takeda, Emalex, Akili, Ironshore, AEVI Genomic Medicine, Neos, Otsuka, Pfizer, Purdue, Rhodes, Sunovion, Tris, KemPharm, Supernus, US Food and Drug Administration, Arbor

Consulting Fees (eg, Ad Boards)

Takeda, Akili, TuLex, Cingulate, Otsuka, Ironshore, Purdue, Adlon, Rhodes, Tris, KemPharm, NLS Pharma, Sunovion, Jazz, Supernus

Speakers’ Bureau

Takeda, Tris, Neos, Supernus, Ironshore

Samuele Cortese, MD, PhD

No disclosures to report

Andrew J. Cutler, MD

Consulting fees (eg, Ad Boards)

AbbVie, Acadia, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Atentive, Cognitive Research, Intra-Cellular Therapies, lronshore, Janssen, Lundbeck, MedAvante­Prophase, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Terran Biosciences, Teva

Grants/Research Support

Aevi Genomics, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Intra­Cellular Therapies, Lilly, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris

Honoraria

AbbVie, Acadia, Alfasigma, Alkermes, Allergan, Intra-Cellular Therapies, lronshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

Tanya E. Froehlich, MD

No disclosures to report

Scott H. Kollins, PhD

Grants/Research Support

Akili, Bose, Tris, Tali Health, Sana Health, OnDosis, BehaVR

Consulting Fees (eg, Ad Boards)

Akili, Bose, Otsuka

Ownership Interest/Shareholder

Akili, Behavioral Innovations Group

Gregory W. Mattingly, MD

Grants/Research Support

Akili, Alkermes, Allergan, Boehringer, Janssen, Medgenics, NLS-1 Pharma AG, Otsuka, Reckitt Benckiser, Roche, Sage, Sunovion, Supernus, and Takeda

Consulting Fees (eg, Ad Boards)

Akili, Alkermes, Allergan, Axsome, lronshore, Intracellular, Janssen, Lundbeck, Otsuka, Neas, Purdue, Rhodes, Sage, Shire, Sunovion, Takeda, and Teva

Speakers’ Bureau

Alkermes, Allergan, Janssen, Lundbeck, Otsuka, Sunovion, and Takeda

Jesse McClelland, MD, MPh

No disclosures to report

James J. McGough, MD

Consulting Fees (eg, Ad Boards)

Sunovion – DSMB Honoraria

Jeffrey Newcorn, MD

Grants/Research Support

Shire, Otsuka, Supernus

Consulting Fees (advisor and/or consultant)

Adlon, Arbor, Cingulate Therapeutics, Eisai, Ironshore, Medice, Myriad Neuroscience, NLS, OnDosis, Rhodes, Shire/Takeda, Supernus

Speakers’ Bureau

Disease state lectures for program funded by Takeda

Steven Pliszka, MD

Grants/Research Support

Otsuka Pharmaceutical

Consulting Fees (eg, Ad Boards)

Adlon

Speakers’ Bureau

Ironshore Pharma

Anthony L. Rostain, MD, MA

Consulting Fees (eg, Ad Boards)

National Football League, Tris Pharma, Inc., Shire, a Takeda Company, Arbor Pharmaceuticals, LLC

Royalty/Patent Holders

St. Martin’s Press and Routledge – Taylor & Francis Group

Timothy E. Wilens, MD

Clinical Consulting

Gavin Foundation, Bay Cove Human Services, US National Football League (ERM Associates), US Minor/Major League Baseball

Consulting on Psychopharmacology / Products for ADHD (Remuneration to MGH, no personal income)

Arbor Pharmaceuticals, Ironshore, Otsuka, KemPharm, Vallon

Royalty/Patent Holder

Ironshore – Licensing agreement: Co-owner of copyrighted diagnostic questionnaire, the Before School Functioning Questionnaire

Guilford Press – Published book: Straight Talk About Psychiatric Medications for Kids

Cambridge University Press – Co/edited textbook: ADHD in Adults and Children


The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity: 


Name

Reported Financial Relationship

Stephen V. Faraone, PhD

In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from Takeda, OnDosis, Tris, Otsuka, Arbor, Ironshore, Rhodes, Akili Interactive Labs, Enzymotec, Sunovion, Supernus and Genomind.  With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD.  He also receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier: ADHD: Non-Pharmacologic Interventions.  He is Program Director of www.adhdinadults.com.

Lee Sullivan, Veritas Institute for Medical Education, Inc.

No financial relationships to disclose

Planners at Medical Education Resources

No financial relationships to disclose

Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Veritas Institute for Medical Education, Inc., American Professional Society of ADHD and Related Disorders, and/or Ironshore Pharmaceuticals, Supernus Pharmaceuticals, or QB Tech. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Veritas Institute for Medical Education, Inc., American Professional Society of ADHD and Related Disorders, and/or Ironshore Pharmaceuticals, Supernus Pharmaceuticals, or QB Tech. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Fee Information
There is no fee for this educational activity.